#Taiwan #Frankfurt #TCM #CPHI

Taiwan's Innovative Showcase at CPHI Frankfurt 2025

Taiwan's healthcare system has garnered international acclaim, recently being ranked as the top healthcare system in the world by CEOWORLD Magazine's 2024 Health Care Index. This ranking underscores Taiwan’s commitment to blending modern medical practices with the rich heritage of Traditional Chinese Medicine (TCM). At the upcoming CPHI Frankfurt 2025, the Taiwan pavilion will spotlight how the country harnesses scientific validation alongside centuries-old botanical wisdom to create cutting-edge health solutions.

The pavilion, found at stand 12.1 C112, aims to present a detailed narrative of Taiwan’s advancements in TCM, showcasing how these innovations contribute significantly to global health initiatives. Among the prodigious achievements are the NRICM series of TCM innovations developed by the National Research Institute of Chinese Medicine (NRICM). These range from solutions targeting COVID-19 (NRICM101 and NRICM102) to significant treatments for dementia (NRICM201) and post-stroke recovery (NRICM301). Notably, NRICM101 and NRICM102 gained worldwide recognition during the pandemic as exemplary evidence-based TCM products, making their commercial debut prior to others.

One of the notable contributors to these advancements is Chuang Song Zong, a heritage company with a 150-year legacy. They play a crucial role in manufacturing NRICM101, which is now exported to markets like Singapore and Thailand while also supplying classical TCM products in regions, including Switzerland. They're also involved in custom OEM/ECM offerings for both TCM and dietary supplements.

Another key player, Li Kang Biotech, brings both NRICM101 and NRICM201 to the international stage, along with a wide array of teas, herbal granules, supplements, and topical remedies, supported by their GMP certification and ODM/OEM expertise for foreign market expansion. Furthermore, Timing Pharmaceutical also manufactures NRICM101, exemplifying the collective effort of Taiwan's traditional medicine sector during the pandemic. Their president, Yung-Ning Chan, emphasized the dedication shown by the team to fulfill pressing demands domestically and internationally, amidst a global crisis. Today, they expand their portfolio with innovative products like K-Cup plant capsules and topical sprays.

Specializing in pain relief products, Taiwan Three Mast transforms traditional remedies into contemporary applications with their water-based medicated patches and functional herbal tablets designed for everyday use. Grape King Bio further enriches the landscape with its unique combination of herbal TCM formulations and biotechnological innovations, producing nutraceuticals aimed at enhancing immune health and metabolic functions.

Dr. Yi-Chang Su, who oversees both the Department of Chinese Medicine and Pharmacy and the NRICM under Taiwan's Ministry of Health and Welfare, proudly states, "Taiwan has demonstrated that traditional medicine can aptly complement modern healthcare when grounded in scientific validation."

At the CPHI Frankfurt exhibition, the Taiwan pavilion plans to conduct product demonstrations and business networking events, inviting health professionals, distributors, and potential partners to delve into the bright future of evidence-based TCM. This commitment to international collaboration promises to foster innovation and expand the reach of TCM solutions worldwide.

More than a showcase, Taiwan's participation at CPHI 2025 serves as a testament to the viability of traditional practices in contemporary global health landscapes, emphasizing an ongoing commitment to integration, innovation, and mutually beneficial partnerships.